Pfizer Total Liabilities increased by 5.0% to $121.39B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.8%, from $124.90B to $121.39B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 6.0% CAGR.
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
total_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $99.61B | $103.22B | $104.01B | $101.16B | $107.82B | $102.46B | $101.29B | $94.38B | $120.88B | $117.82B | $137.21B | $128.54B | $128.22B | $126.92B | $124.90B | $117.39B | $117.08B | $115.64B | $121.39B |
| QoQ Change | — | +3.6% | +0.8% | -2.7% | +6.6% | -5.0% | -1.1% | -6.8% | +28.1% | -2.5% | +16.5% | -6.3% | -0.2% | -1.0% | -1.6% | -6.0% | -0.3% | -1.2% | +5.0% |
| YoY Change | — | — | — | — | +8.2% | -0.7% | -2.6% | -6.7% | +12.1% | +15.0% | +35.5% | +36.2% | +6.1% | +7.7% | -9.0% | -8.7% | -8.7% | -8.9% | -2.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.